Capricor Therapeutics (NASDAQ:CAPR) Trading Down 4.7% – Should You Sell?

Capricor Therapeutics Inc (NASDAQ:CAPR)’s stock price fell 4.7% during mid-day trading on Thursday . The company traded as low as $12.91 and last traded at $12.56. 519,153 shares changed hands during trading, a decline of 63% from the average session volume of 1,387,494 shares. The stock had previously closed at $13.18.

Analyst Upgrades and Downgrades

CAPR has been the topic of several research reports. HC Wainwright reiterated a “buy” rating and set a $77.00 target price on shares of Capricor Therapeutics in a research note on Monday, March 17th. Cantor Fitzgerald reiterated an “overweight” rating and issued a $30.00 price objective on shares of Capricor Therapeutics in a research note on Thursday, March 20th. One research analyst has rated the stock with a sell rating and six have issued a buy rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $34.50.

Capricor Therapeutics Stock Down 2.6 %

The stock has a market capitalization of $522.91 million, a price-to-earnings ratio of -10.85 and a beta of 4.10. The business’s 50 day simple moving average is $14.00 and its 200-day simple moving average is $14.84.

Capricor Therapeutics (NASDAQ:CAPR) last posted its quarterly earnings results on Wednesday, March 19th. The biotechnology company reported ($0.16) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.31) by $0.15. Capricor Therapeutics had a negative net margin of 146.86% and a negative return on equity of 112.95%. The business had revenue of $11.13 million for the quarter, compared to analyst estimates of $9.87 million. On average, analysts expect that Capricor Therapeutics Inc will post -1.21 earnings per share for the current year.

Institutional Trading of Capricor Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the business. Summit Investment Advisors Inc. boosted its stake in shares of Capricor Therapeutics by 54.1% in the 4th quarter. Summit Investment Advisors Inc. now owns 3,832 shares of the biotechnology company’s stock valued at $53,000 after purchasing an additional 1,345 shares in the last quarter. Russell Investments Group Ltd. boosted its position in Capricor Therapeutics by 172.8% in the fourth quarter. Russell Investments Group Ltd. now owns 4,652 shares of the biotechnology company’s stock valued at $64,000 after buying an additional 2,947 shares in the last quarter. Virtus ETF Advisers LLC bought a new stake in shares of Capricor Therapeutics during the fourth quarter worth $68,000. AlphaQuest LLC bought a new position in shares of Capricor Therapeutics in the 4th quarter valued at $78,000. Finally, New York State Common Retirement Fund boosted its holdings in shares of Capricor Therapeutics by 625.0% during the 4th quarter. New York State Common Retirement Fund now owns 5,800 shares of the biotechnology company’s stock valued at $80,000 after acquiring an additional 5,000 shares in the last quarter. 21.68% of the stock is currently owned by institutional investors.

About Capricor Therapeutics

Capricor Therapeutics, Inc (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.